PLRX Pliant Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PLRX

Price (delayed)

$13.89

Market cap

$831.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.79

Enterprise value

$786.36M

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual ...

Highlights
The company's quick ratio rose by 38% YoY
Pliant Therapeutics's debt has decreased by 28% YoY and by 17% QoQ
The equity has grown by 49% YoY but it has contracted by 6% from the previous quarter
The revenue has dropped by 64% year-on-year and by 29% since the previous quarter
PLRX's gross profit has dropped by 64% year-on-year and by 29% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://pliantrx.com
Peers: OGN

Key stats

What are the main financial stats of PLRX
Market
Shares outstanding
59.9M
Market cap
$831.95M
Enterprise value
$786.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.65
Price to sales (P/S)
233.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
221.82
Earnings
Revenue
$3.55M
EBIT
-$153.55M
EBITDA
-$149.29M
Free cash flow
-$123.52M
Per share
EPS
-$2.79
Free cash flow per share
-$2.07
Book value per share
$8.41
Revenue per share
$0.06
TBVPS
$9.05
Balance sheet
Total assets
$540.46M
Total liabilities
$37.42M
Debt
$12.08M
Equity
$503.05M
Working capital
$506.94M
Liquidity
Debt to equity
0.02
Current ratio
19.5
Quick ratio
19.11
Net debt/EBITDA
0.31
Margins
EBITDA margin
-4,211.2%
Gross margin
100%
Net margin
-4,380.5%
Operating margin
-4,922.7%
Efficiency
Return on assets
-30.1%
Return on equity
-32.5%
Return on invested capital
-34.7%
Return on capital employed
-29.9%
Return on sales
-4,331.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLRX stock price

How has the Pliant Therapeutics stock price performed over time
Intraday
0%
1 week
-0.29%
1 month
-0.43%
1 year
-24.43%
YTD
-28.14%
QTD
-19.9%

Financial performance

How have Pliant Therapeutics's revenue and profit performed over time
Revenue
$3.55M
Gross profit
$3.55M
Operating income
-$174.51M
Net income
-$155.29M
Gross margin
100%
Net margin
-4,380.5%
The revenue has dropped by 64% year-on-year and by 29% since the previous quarter
PLRX's gross profit has dropped by 64% year-on-year and by 29% since the previous quarter
The operating margin has plunged by 56% from the previous quarter
PLRX's operating income has dropped by 53% year-on-year and by 10% since the previous quarter

Growth

What is Pliant Therapeutics's growth rate over time

Valuation

What is Pliant Therapeutics stock price valuation
P/E
N/A
P/B
1.65
P/S
233.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
221.82
The EPS has grown by 4.8% year-on-year
The equity has grown by 49% YoY but it has contracted by 6% from the previous quarter
PLRX's price to book (P/B) is 34% lower than its last 4 quarters average of 2.5
The revenue has dropped by 64% year-on-year and by 29% since the previous quarter
The P/S is 26% more than the last 4 quarters average of 185.4

Efficiency

How efficient is Pliant Therapeutics business performance
The return on sales has dropped by 53% since the previous quarter
The company's return on invested capital rose by 39% YoY
The ROE is up by 38% year-on-year
Pliant Therapeutics's return on assets has increased by 35% YoY

Dividends

What is PLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLRX.

Financial health

How did Pliant Therapeutics financials performed over time
The company's total assets rose by 43% YoY but it fell by 6% QoQ
Pliant Therapeutics's current ratio has increased by 39% YoY
Pliant Therapeutics's debt is 98% lower than its equity
PLRX's debt to equity has dropped by 60% year-on-year and by 33% since the previous quarter
The equity has grown by 49% YoY but it has contracted by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.